Catalyst Pharmaceutical News Releases https://ir.catalystpharma.com/ Catalyst Pharmaceutical News Releases en Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-first-quarter-2019-financial -FirdapseĀ® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla. Mon, 13 May 2019 06:03:00 -0400 Catalyst Pharmaceutical News Releases 12866 Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 13th, 2019 https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-hold-first-quarter-financial-results-3 CORAL GABLES, Fla. , May 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Mon, 06 May 2019 08:03:00 -0400 Catalyst Pharmaceutical News Releases 12851 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-3 CORAL GABLES, Fla. , March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Mon, 18 Mar 2019 16:20:00 -0400 Catalyst Pharmaceutical News Releases 12816 Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019 https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-hold-fourth-quarter-financial-results-1 CORAL GABLES, Fla. , March 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Mon, 11 Mar 2019 04:03:00 -0400 Catalyst Pharmaceutical News Releases 12801 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019 https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-support-rare-disease-day-2019 CORAL GABLES, Fla. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Thu, 28 Feb 2019 08:03:00 -0500 Catalyst Pharmaceutical News Releases 12791 Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for FirdapseĀ® for the Treatment of Lambert-Eaton Myasthenic Syndrome https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-publication-phase-3-clinical CORAL GABLES, Fla. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Tue, 26 Feb 2019 08:03:00 -0500 Catalyst Pharmaceutical News Releases 12781 Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-responds-letter-senator-bernie-sanders CORAL GABLES, Fla. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic, neuromuscular and neurological diseases, today Thu, 21 Feb 2019 09:00:00 -0500 Catalyst Pharmaceutical News Releases 12776 Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-present-21st-annual-bio-ceo-investor CORAL GABLES, Fla. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Tue, 05 Feb 2019 08:03:00 -0500 Catalyst Pharmaceutical News Releases 12731 Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating FirdapseĀ® for the Treatment of MuSK Antibody Positive Myasthenia Gravis https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-publication-clinical-data Published online in SAGE Open Medicine on December 17, 2018 CORAL GABLES, Fla. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, Fri, 04 Jan 2019 08:03:00 -0500 Catalyst Pharmaceutical News Releases 12721 Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-definitive-agreement-endo CORAL GABLES, Fla. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today Tue, 18 Dec 2018 11:40:00 -0500 Catalyst Pharmaceutical News Releases 12646